EXHIBIT 2030

Fujisawa Deutschland GmbH

CERTIFICATE OF ANALYSIS

Bendamustin 100 mg for injection, Batch no. 03H07

Expiry Date: 08.2005

TI no.: 3.0

Test parameter	Specification	Result
General characteristics		
Appearance	white, microcrystalline lyophilisate	complies
Average mass	198.0 – 242.0 mg	222.3 mg
Uniformity of mass	complies with Ph. Eur. 2.9.5	complies
Solubility	soluble within 5 minutes without residues	complies
Clarity after reconstitution	clear	complies
Colour after reconstitution	≤ B 6	complies
pH-value after reconstitution	2.5 – 3.5	3.2
Identity		
- Chloride - Bendamustine hydrochloride	positive complies with standard	complies complies
Purity		
Related substances - HP 1 - HP 2 - NP 1 - BM1EE - HBI - Not identified singel peaks - Sum of not identified peaks - Sum of all secondary peaks	 max. 3.5 % max. 0.5 % max. 0.5 % max. 0.5 % max. 0.5 % max. 0.2 % max. 0.5 % max. 5.0 %	 1.8 % n.d. <LOQ 0.2 % n.d. n.d. 0.3 % 2.4 %
Water content	max. 2.5 %	1.9 %
Sterility	sterile, complies with Ph. Eur. 2.6.1	complies
Endotoxins	not more than 0.5 I.U. / mg	complies
Assay		
Bendamustine hydrochloride	100.0 mg / vial (limits: 95.0 – 105.0 mg / vial)	99.6 mg / vial

We herewith confirm that this batch was manufactured and tested in accordance with the relevant GMP requirements.
Status: Approved for clinical trials

Munich, October 2nd, 2003

Dr. Unterlinner
Head of Product Release/QC

Fuchs
Product Documentation/QC

Administrative headquarters:
Berg-am-Laim-Strasse 129
D-81673 München
Telefax: +49(0)89 45 44-13 29

Operations:
Weihenstephaner Strasse 28
D-81673 München
Telefax: +49(0)89 45 44-15 95

Telephone:
+49(0)89 45 44-01
V.A.T. No:
DE 811188277

E-mail:
info@fujisawa-deutschland.de
Website:
www.fujisawa-deutschland.de

Dresdner Bank München
acct. # 03 017 825 00
Bank ID Code: 700 800 00
SWIFT-address: DRES DE FF 700

Stadtsparkasse München
acct. # 39-180 039
Bank ID Code: 701 500 00
SWIFT-address: SSKM DE MM AXX

Company Seat: München · Incorporated at the Court Registry in München HR B 67 708 · President: Dr. Wolfgang Tinhof · Executive Vice President: Dipl.-Kfm. Wolfgang Schoch
Executive Directors: Dipl.-Kfm. Norbert Fischer · Dr. Erich Kammerl · Dr. Fritz Stanislaus

F02e (01/02)

THISSEN Laboratories s.a.

Rue de la Papyrée 2-6
B-1420 BRAINE L'ALLEUD
Tel : 32-2-386.12.11
Fax : 32-2-385.17.82

SDX 105 FOR INJECTION

BATCH : 03H07

TEST PARAMETER	TEST METHOD	RELEASE SPECIFICATION	RESULTS
General and specific characteristics			
Appearance	Visual examination	White, microcrystalline lyophilisate	Complies
Uniformity of dosage units	USP <905>	Complies	Complies
Constituted solution	USP <1>	Complies	Complies
pH value after reconstitution	USP <791>	2.5 - 3.5	3.2
Identity			
Bendamustine hydrochloride	HPLC	Complies with standard	Complies
Assay			
Bendamustine hydrochloride	HPLC	100.0 mg / vial 95.0 – 105.0 mg/vial	99.6
Purity			
Water content	USP <921> method 1	Max 2.5 %	1.9
Related substances	HPLC		
HP1		Max 3.3 %	1.8
HP2		Max 0.5 %	ND
HP3		Max 0.1 %	ND
NP1		Max 0.5 %	< LOQ
BM1 EE		Max 0.6 %	0.2
BM1 DIMER		Max 0.7 %	0.3
BM1 DCE		Max 0.1 %	ND
HBI		Max 0.5 %	ND
Not identified single peaks		Max 0.1 %	ND
Sum of not identified peaks		Max 0.5 %	ND
Sum of all secondary peaks		Max 5.0 %	2.4
Sterility	USP <71>	Sterile	Complies
Bacterial endotoxines	USP <85>	Max 0.5 I.U. / mg	< 0.192
Particulate matter	USP <788>	Complies	Complies